Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury

Paused · Phase 1

Conditions studied: Spinal Cord Injury

In brief

This study is based on preclinical (animal) studies showing that infusing bone marrow-derived mesenchymal stem cells into the spinal fluid may contribute to improving neurologic function in animal models with spinal cord injuries. Bone marrow (BM) contains several types of stem cells that can produce functional cells. This includes cells that could help the healing process of damaged neurologic tissue. The primary objective of this study is to see if the injection of these cells, obtained from your own bone marrow, is safe. A secondary objective is to evaluate if the treatment can provide functional improvements (neuromuscular control and sensation) in the affected areas.

Key facts

Study ID

NCT01162915

Run by

TCA Cellular Therapy

People needed

10

Starts

2010-07-01

Expected to finish

2014-05-01

Last updated by the study team

2014-05-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 65
• American Spinal Injury Association Impairment Scale A
• Clinical evidence of lesions located below c-spine 5 (C-5)
• Confirmation by MRI of injury level
• Time between injury and enrollment greater than 2 weeks
• Ability to provide informed consent
• Platelet count greater than 100 Thousand/uL at screening
• INR equal to or less than 1.5
• Hematocrit less than 30% prior to bone marrow aspiration
• Spinal cord injury within 60 months of screening

You may not qualify if…

• Anoxic brain injury
• Inability to provide consent
• Sepsis
• Neurological deficits attributed to lesions above C-5
• Cerebro-vascular accidents with intracranial hemorrhage, acute brain injuries, meningitis, hydrocephalus or other potential diseases where the pressure in the cerebro spinal fluid is increased
• Multiple sclerosis
• Amyotrophic lateral sclerosis
• Cerebral Palsy
• Evidence of cancer over the last 3 years prior to enrollment
• Immunosuppressive diseases
• Platelet count lower than 100,000
• White blood count greater than 15,000 unless the patient is on steroids
• Bleeding disorders
• Clinical or laboratory evidence of meningitis
• Skin infection at the infusion site
• Pregnant or planning to become pregnant

Where it is running

• TCA Cellular Therapy, LLC — Covington, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.